# IMPROEV (NCT07221942)

> Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma

No report yet. It can be ordered.

- Drugs tested: enfortumab vedotin plus pembrolizumab

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07221942
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Fox Chase Cancer Center
- Conditions: Metastatic Urothelial Carcinoma; Unresectable Urothelial Carcinoma; Advanced Urothelial Carcinoma
- Interventions: Enfortumab vedotin; Pembrolizumab
- Enrollment: 97
- Primary outcome: 18-month progression-free survival (PFS)

## Indexed commentary on IMPROEV so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X
- 1 YouTube video

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=improev-nct07221942